Preferred Label : Axitinib;
MeSH definition : A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced
RENAL CELL CARCINOMA.;
MeSH hyponym : AG013736; AG-013736;
MeSH CAS label : Benzamide, N-methyl-2-((3-((E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)-;
UNII : C9LVQ0YUXG;
Origin ID : D000077784;
UMLS CUI : C1700874;
ATC code(s)
- Allowable qualifiers
- Automatic exact mappings (from CISMeF team)
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced
RENAL CELL CARCINOMA.
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-VEGFR-axitinib-cabozantinib-pazopanib-sorafenib-sunitinib
2019
false
false
false
France
Axitinib
cabozantinib
pazopanib
Sorafenib
Sunitinib
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
risk factors
patient education as topic
continuity of patient care
administration, oral
receptors, vascular endothelial growth factor
carcinoma, renal cell
drug interactions
pregnancy
Tyrosine Kinase Inhibitors
guidelines for drug use
Sorafenib
pazopanib
Axitinib
Sunitinib
cabozantinib
pyrimidines
sulfonamides
anilides
pyridines
pyrimidines
sulfonamides
anilides
pyridines
anilides
pyridines
pyrimidines
sulfonamides
---
http://www.has-sante.fr/portail/jcms/c_1720122/fr/inlyta
2014
false
France
French
administration, oral
insurance, health, reimbursement
evaluation of the transparency committee
axitinib
carcinoma, renal cell
protein kinase inhibitors
protein kinase inhibitors
adult
angiogenesis inhibitors
angiogenesis inhibitors
treatment outcome
clinical trials, phase iii as topic
disease-free survival
survival analysis
Axitinib
Axitinib
---
http://www.meddispar.fr/Medicaments/INLYTA-3-B-56/%28type%29/letter/%28value%29/I/%28cip%29/3400927547379
2014
false
false
false
France
French
drug information
administration, oral
drug prescriptions
legislation, drug
axitinib
continuity of patient care
antineoplastic agents
imidazoles
indazoles
Axitinib
---
http://www.meddispar.fr/Medicaments/INLYTA-7-B-56/%28type%29/letter/%28value%29/I/%28cip%29/3400927547669
2014
false
true
false
France
French
drug information
administration, oral
drug prescriptions
legislation, drug
axitinib
continuity of patient care
antineoplastic agents
imidazoles
indazoles
Axitinib
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64922489
2014
false
false
false
France
French
summary of product characteristics
package leaflet
tablets
axitinib
compression, nos
axitinib
dandruff
pill, nos
seborrhea sicca
dandruff
imidazoles
indazoles
Axitinib
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=67939209
2014
false
false
false
France
French
summary of product characteristics
package leaflet
axitinib
compression, nos
pill, nos
dandruff
tablets
seborrhea sicca
axitinib
dandruff
imidazoles
indazoles
Axitinib
---
http://www.meddispar.fr/Medicaments/INLYTA-1-B-56/(type)/letter/(value)/I/(cip)/3400926648046
2014
false
false
false
France
French
drug information
administration, oral
antineoplastic agents
drug prescriptions
legislation, drug
axitinib
continuity of patient care
imidazoles
indazoles
Axitinib
---
http://www.meddispar.fr/Medicaments/INLYTA-5-B-56/(type)/letter/(value)/I/(cip)/3400926648275
2014
false
false
false
France
French
drug information
administration, oral
drug prescriptions
legislation, drug
axitinib
continuity of patient care
antineoplastic agents
imidazoles
indazoles
Axitinib
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=64922489
2013
summary of product characteristics
tablets
Axitinib
---
http://www.has-sante.fr/portail/jcms/c_1356128/inlyta
http://www.has-sante.fr/portail/jcms/c_1356127/inlyta-09012013-avis-ct12556
2013
false
France
French
administration, oral
insurance, health, reimbursement
evaluation of the transparency committee
axitinib
carcinoma, renal cell
protein kinase inhibitors
protein kinase inhibitors
adult
angiogenesis inhibitors
angiogenesis inhibitors
treatment outcome
clinical trials, phase iii as topic
disease-free survival
survival analysis
Axitinib
Axitinib
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67939209
2013
summary of product characteristics
tablets
Axitinib
---
Summary Basis of Decision (SBD) for Inlyta
Axitinib, 1 mg and 5 mg, Tablet, Oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00071
2012
false
Canada
French
English
clear-cell metastatic renal cell carcinoma
drug information
Axitinib 1mg tablet (product)
Axitinib 5mg tablet (product)
Tyrosine Kinase Inhibitors
drug approval
canada
administration, oral
axitinib
neoplasm metastasis
protein kinase inhibitors
protein kinase inhibitors
carcinoma, renal cell
vascular endothelial growth factor receptor-1
vascular endothelial growth factor receptor-2
vascular endothelial growth factor receptor-3
drug evaluation, preclinical
treatment outcome
clinical trials, phase iii as topic
risk assessment
Axitinib
Axitinib
---
https://www.ema.europa.eu/medicines/human/EPAR/Inlyta
2012
false
United Kingdom
French
English
Metastatic Kidney Carcinoma
Tyrosine Kinase Inhibitors
axitinib
administration, oral
adult
aged
breast feeding
carcinoma, renal cell
continuity of patient care
drug interactions
drug evaluation, preclinical
fertility
pregnancy
protein-tyrosine kinases
treatment outcome
drug approval
clinical trials, phase iii as topic
disease-free survival
receptors, vascular endothelial growth factor
protein kinase inhibitors
protein kinase inhibitors
Axitinib
Axitinib
drug evaluation
syndication feed
summary of product characteristics
package leaflet
---
